ZHONG YUAN BIO-TECHNOLOGY HOLDINGS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5 USD | +11.11% |
|
-1.77% | +146.31% |
Financials (USD)
| Sales 2022 | 2.33M | Sales 2023 | 1.66M | Capitalization | 65.94M |
|---|---|---|---|---|---|
| Net income 2022 | -1M | Net income 2023 | -2M | EV / Sales 2022 | 51.2 x |
| Net Debt 2022 | 1.55M | Net Debt 2023 | 1.76M | EV / Sales 2023 | 40.7 x |
| P/E ratio 2022 |
-103
x | P/E ratio 2023 |
-29.5
x | Employees | 35 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 35.07% |
More Fundamentals
* Assessed data
More news
| 1 day | +11.11% | ||
| 1 week | -1.77% | ||
| 1 month | +0.20% | ||
| 3 months | +150.00% | ||
| 6 months | +4.17% | ||
| Current year | +146.31% |
1 week
4.50
5.02
1 month
4.505.23
Current year
1.476.00
1 year
1.236.00
3 years
0.237.59
5 years
0.237.59
10 years
0.237.59
| Managers | Title | Age | Since |
|---|---|---|---|
Ting Ting Chang
CEO | Chief Executive Officer | 34 | 17-05-02 |
Fung Ming Pang
DFI | Director of Finance/CFO | 53 | 20-05-03 |
Xianyang Chen
CTO | Chief Tech/Sci/R&D Officer | 40 | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chi Wai Tse
BRD | Director/Board Member | 57 | 22-07-31 |
Ting Ting Chang
CEO | Chief Executive Officer | 34 | 17-05-02 |
Fung Ming Pang
DFI | Director of Finance/CFO | 53 | 20-05-03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 5 | +11.11% | 277 |
| 24-04-23 | 4.5 | -10.00% | 200 |
| 24-04-22 | 5 | -0.40% | 300 |
| 24-04-19 | 5.02 | +0.40% | 100 |
| 24-04-18 | 5 | -1.77% | 200 |
Delayed Quote OTC Markets, April 24, 2024 at 10:10 am EDT
More quotes
Zhong Yuan Bio-Technology Holdings Ltd is an investment holding company principally engaged in the development and sale of health supplements. The Company operates its business through two segments. The Sales of Health Care Supplements segment is engaged in the development and sale of new drugs for neurological disorders, brain disease detection kits, the sale of plant-derived nervonic acid health supplements as well as others. The Company's main products are nervonic acid series supplements, marketed under the 'Muzhiyuan Neuro Enhancer' brand. The Technical Supporting Services segment is engaged in the provision of technical services.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +146.31% | 88.5M | |
| +25.61% | 660B | |
| +22.52% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +13.42% | 219B | |
| -9.65% | 196B | |
| +6.63% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- ZHYBF Stock
